Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
Add more filters

Country/Region as subject
Publication year range
1.
J Exp Med ; 191(3): 423-34, 2000 Feb 07.
Article in English | MEDLINE | ID: mdl-10662788

ABSTRACT

Cell death by necrosis is typically associated with inflammation, in contrast to apoptosis. We have identified additional distinctions between the two types of death that occur at the level of dendritic cells (DCs) and which influence the induction of immunity. DCs must undergo changes termed maturation to act as potent antigen-presenting cells. Here, we investigated whether exposure to apoptotic or necrotic cells affected DC maturation. We found that immature DCs efficiently phagocytose a variety of apoptotic and necrotic tumor cells. However, only exposure to the latter induces maturation. The mature DCs express high levels of the DC-restricted markers CD83 and lysosome-associated membrane glycoprotein (DC-LAMP) and the costimulatory molecules CD40 and CD86. Furthermore, they develop into powerful stimulators of both CD4(+) and CD8(+) T cells. Cross-presentation of antigens to CD8(+) T cells occurs after uptake of apoptotic cells. We demonstrate here that optimal cross-presentation of antigens from tumor cells requires two steps: phagocytosis of apoptotic cells by immature DCs, which provides antigenic peptides for major histocompatibility complex class I and class II presentation, and a maturation signal that is delivered by exposure to necrotic tumor cells, their supernatants, or standard maturation stimuli, e.g., monocyte-conditioned medium. Thus, DCs are able to distinguish two types of tumor cell death, with necrosis providing a control that is critical for the initiation of immunity.


Subject(s)
Apoptosis , Dendritic Cells/physiology , Immune Tolerance/physiology , Neoplasms/immunology , Animals , Antigen-Presenting Cells/immunology , Apoptosis/immunology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cell Line , Culture Media , Dendritic Cells/immunology , Humans , Lymphocyte Activation , Mice , Necrosis , Neoplasms/pathology , Phagocytosis , Phenotype , Signal Transduction , Tumor Cells, Cultured , Ultraviolet Rays
2.
J Exp Med ; 186(12): 2075-80, 1997 Dec 15.
Article in English | MEDLINE | ID: mdl-9396779

ABSTRACT

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine) is a new member of the TNF family that is induced upon T cell receptor engagement and activates c-Jun N-terminal kinase (JNK) after interaction with its putative receptor (TRANCE-R). In addition, TRANCE expression is restricted to lymphoid organs and T cells. Here, we show that high levels of TRANCE-R are detected on mature dendritic cells (DCs) but not on freshly isolated B cells, T cells, or macrophages. Signaling by TRANCE-R appears to be dependent on TNF receptor-associated factor 2 (TRAF2), since JNK induction is impaired in cells from transgenic mice overexpressing a dominant negative TRAF2 protein. TRANCE inhibits apoptosis of mouse bone marrow-derived DCs and human monocyte-derived DCs in vitro. The resulting increase in DC survival is accompanied by a proportional increase in DC-mediated T cell proliferation in a mixed leukocyte reaction. TRANCE upregulates Bcl-xL expression, suggesting a potential mechanism for enhanced DC survival. TRANCE does not induce the proliferation of or increase the survival of T or B cells. Therefore, TRANCE is a new DC-restricted survival factor that mediates T cell-DC communication and may provide a tool to selectively enhance DC activity.


Subject(s)
Carrier Proteins , Cytokines/physiology , Dendritic Cells/cytology , Membrane Glycoproteins/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Apoptosis , B-Lymphocytes/cytology , Bone Marrow Cells/cytology , CD40 Ligand , Cell Separation , Cell Survival , Flow Cytometry , Humans , Mice , Mice, Transgenic , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/genetics , RANK Ligand , RNA, Messenger/metabolism , Receptor Activator of Nuclear Factor-kappa B , T-Lymphocytes/cytology , Up-Regulation , bcl-X Protein
3.
J Exp Med ; 188(7): 1359-68, 1998 Oct 05.
Article in English | MEDLINE | ID: mdl-9763615

ABSTRACT

Dendritic cells, but not macrophages, efficiently phagocytose apoptotic cells and cross-present viral, tumor, and self-antigens to CD8(+) T cells. This in vitro pathway corresponds to the in vivo phenomena of cross-priming and cross-tolerance. Here, we demonstrate that phagocytosis of apoptotic cells is restricted to the immature stage of dendritic cell (DC) development, and that this process is accompanied by the expression of a unique profile of receptors, in particular the alphavbeta5 integrin and CD36. Upon maturation, these receptors and, in turn, the phagocytic capacity of DCs, are downmodulated. Macrophages engulf apoptotic cells more efficiently than DCs, and although they express many receptors that mediate this uptake, they lack the alphavbeta5 integrin. Furthermore, in contrast to DCs, macrophages fail to cross-present antigenic material contained within the engulfed apoptotic cells. Thus, DCs use unique pathways for the phagocytosis, processing, and presentation of antigen derived from apoptotic cells on class I major histocompatibility complex. We suggest that the alphavbeta5 integrin plays a critical role in the trafficking of exogenous antigen by immature DCs in this cross-priming pathway.


Subject(s)
Antigen Presentation/immunology , Apoptosis , CD36 Antigens/metabolism , Dendritic Cells/immunology , Dendritic Cells/metabolism , Integrins/metabolism , Phagocytosis , Receptors, Vitronectin , T-Lymphocytes, Cytotoxic/immunology , Antigens, CD , Cells, Cultured , Histocompatibility Antigens Class I/immunology , Humans , Immunoglobulins/metabolism , Macrophages/metabolism , Membrane Glycoproteins/metabolism , CD83 Antigen
4.
J Exp Med ; 188(11): 2163-73, 1998 Dec 07.
Article in English | MEDLINE | ID: mdl-9841929

ABSTRACT

Cells from the bone marrow can present peptides that are derived from tumors, transplants, and self-tissues. Here we describe how dendritic cells (DCs) process phagocytosed cell fragments onto major histocompatibility complex (MHC) class II products with unusual efficacy. This was monitored with the Y-Ae monoclonal antibody that is specific for complexes of I-Ab MHC class II presenting a peptide derived from I-Ealpha. When immature DCs from I-Ab mice were cultured for 5-20 h with activated I-E+ B blasts, either necrotic or apoptotic, the DCs produced the epitope recognized by the Y-Ae monoclonal antibody and stimulated T cells reactive with the same MHC-peptide complex. Antigen transfer was also observed with human cells, where human histocompatibility leukocyte antigen (HLA)-DRalpha includes the same peptide sequence as mouse I-Ealpha. Antigen transfer was preceded by uptake of B cell fragments into MHC class II-rich compartments. Quantitation of the amount of I-E protein in the B cell fragments revealed that phagocytosed I-E was 1-10 thousand times more efficient in generating MHC-peptide complexes than preprocessed I-E peptide. When we injected different I-E- bearing cells into C57BL/6 mice to look for a similar phenomenon in vivo, we found that short-lived migrating DCs could be processed by most of the recipient DCs in the lymph node. The consequence of antigen transfer from migratory DCs to lymph node DCs is not yet known, but we suggest that in the steady state, i.e., in the absence of stimuli for DC maturation, this transfer leads to peripheral tolerance of the T cell repertoire to self.


Subject(s)
Antigen Presentation , Dendritic Cells/immunology , Histocompatibility Antigens Class II/immunology , Phagocytosis/immunology , Animals , Dendritic Cells/cytology , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL
5.
Transpl Infect Dis ; 10(2): 137-41, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17605735

ABSTRACT

Strongyloides stercoralis is a helminth with the ability to autoinfect the human host and persist asymptomatically for several years. Immunosuppression can accelerate autoinfection and result in Strongyloides hyperinfection syndrome (SHS), which is associated with significant morbidity and mortality. Immunosuppressed solid organ transplant recipients, particularly in the setting of rejection, are at increased risk for reactivation of latent infections, such as Strongyloides. We describe a case of SHS in an intestinal transplant recipient; we hypothesize that she acquired the infection from the donor. We also review the current literature and address both prophylaxis and treatment of strongyloidiasis in the solid organ transplant patient.


Subject(s)
Anthelmintics/therapeutic use , Immunocompromised Host , Intestines/transplantation , Strongyloides stercoralis/pathogenicity , Strongyloidiasis/diagnosis , Animals , Female , Humans , Middle Aged , Postoperative Complications , Strongyloidiasis/drug therapy , Strongyloidiasis/etiology , Syndrome , Treatment Outcome
6.
J Natl Cancer Inst ; 92(11): 931-6, 2000 Jun 07.
Article in English | MEDLINE | ID: mdl-10841829

ABSTRACT

BACKGROUND: The success of immunomodulatory cancer therapy is frequently hampered by the transient nature of the antitumor immune response. We have shown previously in a mouse model that interleukin 12 (IL-12) generates a strong natural killer (NK) cell-mediated antitumor response and reduces liver metastases induced by a colon carcinoma cell line. However, only a small percentage of the treated animals developed the cytotoxic T-lymphocytic response required for a long-term systemic antitumor immunity. 4-1BB is a co-stimulatory molecule expressed on the surface of activated T cells. Interaction of 4-1BB with its natural ligand (4-1BBL) has been shown to amplify T-cell (especially CD8+)-mediated immunity. In this study, we investigated the effects of adenovirus-mediated gene therapy delivering both IL-12 and 4-1BBL genes on mice with hepatic metastases induced by colon cancer cells. METHODS: Syngeneic BALB/c mice received intrahepatic injection of poorly immunogenic MCA26 colon cancer cells. Various combinations of replication-defective adenoviruses expressing IL-12 and 4-1BBL genes were injected into the established liver tumors. Changes in tumor size and animal survival were then monitored. All statistical tests were two-sided. RESULTS: The long-term survival rate of mice treated with the combination of IL-12 and 4-1BBL was significantly improved over that of animals in the control group (P =.0001). In vivo depletion of NK cells or CD8+ T cells completely abolished the long-term survival advantage of the IL-12 plus 4-1BBL-treated animals (P<.002). Moreover, the systemic immunity induced by this combination treatment protected these animals against a subcutaneous challenge with parental MCA26 cells. CONCLUSION: Adenovirus-mediated transfer of IL-12 and 4-1BBL genes directly into liver tumors resulted in tumor regression that required both NK and CD8+ T cells and generated a potent, long-lasting antitumor immunity.


Subject(s)
Adjuvants, Immunologic/therapeutic use , CD8-Positive T-Lymphocytes/immunology , Genetic Therapy/methods , Interleukin-12/therapeutic use , Killer Cells, Natural/immunology , Liver Neoplasms/immunology , Liver Neoplasms/therapy , Tumor Necrosis Factor-alpha/therapeutic use , 4-1BB Ligand , Adenoviridae , Adjuvants, Immunologic/genetics , Animals , Colonic Neoplasms/pathology , Disease Models, Animal , Female , Genetic Vectors , Interleukin-12/genetics , Liver Neoplasms/genetics , Liver Neoplasms/secondary , Mice , Mice, Inbred BALB C , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/genetics
7.
Biol Psychiatry ; 46(3): 392-400, 1999 Aug 01.
Article in English | MEDLINE | ID: mdl-10435205

ABSTRACT

BACKGROUND: Our goal was to examine spatial working memory function in relation to clinical symptoms of schizophrenia over a period of 4 months. METHODS: We assessed spatial working memory, spatial detection and clinical symptoms in 34 acutely psychotic schizophrenia patients within the first 2 weeks of hospitalization, and 4 months later. Spatial working memory was assessed by a delayed response task. A spatial control task was included to rule out simple sensorimotor deficits. Positive and negative symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS). Thirty-nine matched normal control subjects were also examined on the same tasks over the same period. RESULTS: Patients showed deficits in working memory, but they performed well on the spatial control task. Both positive and negative symptoms improved at the 4-month follow up. Spatial working memory also improved over time but there was still a significant deficit at the follow-up session. CONCLUSIONS: These results indicate that both symptoms and spatial working memory improved 4 months after the initial hospitalization but spatial working memory, hypothesized to be mediated by the dorsolateral prefrontal system, did not normalize. Thus, spatial working memory deficit may be a stable marker for schizophrenia.


Subject(s)
Memory Disorders/etiology , Perceptual Disorders/etiology , Schizophrenia/complications , Schizophrenic Psychology , Space Perception/physiology , Acute Disease , Adult , Female , Follow-Up Studies , Humans , Male , Memory Disorders/diagnosis , Perceptual Disorders/diagnosis , Prefrontal Cortex/metabolism , Prefrontal Cortex/physiopathology , Psychiatric Status Rating Scales , Schizophrenia/metabolism , Schizophrenia/physiopathology , Time Factors
8.
J Histochem Cytochem ; 46(2): 165-76, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9446823

ABSTRACT

We performed a comparative investigation of the immunomorphological characteristics of lymphatic and blood microvascular endothelial cells in normal human skin, cutaneous lymphangiomas, and hemangiomas, employing a pre-embedding immunogold electron microscopic technique. We stained for cell membrane proteins that are commonly used for light microscopic characterization of blood endothelial cells. With blood microvascular endothelial cells, we observed uniform labeling of the luminal cell membranes with monoclonal antibodies (MAbs) JC70 (CD31), EN-4 (CD31), BMA120, PAL-E, and QBEND-10 (CD34), and strong staining of the vascular basal lamina for Type IV collagen under normal and pathological conditions. In contrast, lymphatic microvascular endothelial cells in normal human skin and in lymphangiomas displayed, in addition to a luminal labeling, pronounced expression of CD31 and CD34 along the abluminal cell membranes. Moreover, CD31 was preferentially detected within intercellular junctions. The expression of CD34 was mostly confined to abluminal endothelial microprocesses and was upregulated in lymphangiomas and hemangiomas. Type IV collagen partially formed the luminal lining of initial lymphatics and occasionally formed bridges over interendothelial gaps. Our findings suggest a function of transmigration protein CD31 in recruitment of dendritic cells into the lymphatic vasculature. CD34 labeling may indicate early endothelial cell sprouting. The distribution of Type IV collagen also supports its role as a signal for migration and tube formation for lymphatic endothelial cells.


Subject(s)
Endothelium, Lymphatic/ultrastructure , Endothelium, Vascular/ultrastructure , Hemangioma/ultrastructure , Lymphangioma/ultrastructure , Skin Neoplasms/ultrastructure , Skin/ultrastructure , Antigens, CD34/analysis , Capillaries/ultrastructure , Collagen/analysis , Endothelium, Lymphatic/chemistry , Endothelium, Lymphatic/cytology , Endothelium, Vascular/chemistry , Endothelium, Vascular/cytology , Hemangioma/blood supply , Humans , Immunohistochemistry , Immunophenotyping , Lymphangioma/blood supply , Microscopy, Immunoelectron , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Skin/blood supply , Skin/cytology , Skin Neoplasms/blood supply
9.
Immunobiology ; 198(5): 552-67, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9561373

ABSTRACT

CD8+ cytolytic T lymphocytes (CTLs) are considered to be critical mediators for resistance to influenza virus infection. We have previously demonstrated that dendritic cells are potent antigen presenting cells in the development of anti-influenza CTLs. Here we identify distinctive features of the interaction of influenza virus with dendritic cells. Exposure of dendritic cells to influenza virus at MOIs of 2-4:1 leads to > 90% infection, as manifested by the expression of the viral proteins HA and NS1. The infection is non-toxic as viral protein expression is sustained for > 2 days with retention of viability, but little infectious virus is produced. Substantial induction of the anti-viral cytokine IFN-alpha also occurs. Influenza infection of macrophages also results in viral protein expression in a majority of cells, and synthesis of IFN-alpha. In contrast to dendritic cells, macrophages display evidence of apoptosis within 10-12 hours, and the majority of cells die within 24-36 hours. During this interval macrophages synthesize > 10-fold higher levels of virus than dendritic cells. Infected dendritic cells but not macrophages, can induce substantial CTL responses from purified blood CD8+ T cells in the absence of exogenous cytokines such as IL-2. Low levels of infection (MOIs of 0.02) are sufficient to generate potent CTL responses. Influenza virus expressing non-cleaved HA does not elicit CTLs indicating that virus must access the cytoplasm of dendritic cells to utilize traditional class I processing pathways. These observations indicate that DCs are distinct in their handling of influenza virus and for the induction of anti-viral immunity.


Subject(s)
Dendritic Cells/immunology , Dendritic Cells/virology , Influenza A virus/immunology , Animals , Antigens, Viral/immunology , Apoptosis , Cell Line , Dogs , Hemagglutinin Glycoproteins, Influenza Virus/biosynthesis , Histocompatibility Antigens Class I/immunology , Humans , Interferon-alpha/biosynthesis , Monocytes/immunology , Monocytes/virology , T-Lymphocytes, Cytotoxic/immunology , Time Factors , Viral Nonstructural Proteins/biosynthesis
10.
Chest ; 105(6): 1871-2, 1994 Jun.
Article in English | MEDLINE | ID: mdl-8205893

ABSTRACT

We describe a 32-year-old man with no history of pulmonary disease who presented with extensive cavernous destruction of the right upper lobe as an incidental finding on a chest x-ray film. All major criteria of allergic bronchopulmonary aspergillosis (ABPA) were present. Histologic examination of the resected lobe showed the typical features of ABPA. The differential diagnosis of multiple cavitating lesions should include ABPA.


Subject(s)
Aspergillosis, Allergic Bronchopulmonary/diagnostic imaging , Adult , Aspergillosis, Allergic Bronchopulmonary/diagnosis , Aspergillosis, Allergic Bronchopulmonary/surgery , Diagnosis, Differential , Humans , Lung/pathology , Male , Pneumonectomy , Tomography, X-Ray Computed
11.
Cortex ; 33(2): 197-217, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9220255

ABSTRACT

An extensive battery of tests of anterograde amnesia and remote memory was given to ten amnesics with lesions either to the medial temporal lobes of the diencephalon. These showed that the patients had anterograde amnesia with deficits in verbal and non-verbal recall and recognition, but preservation of word stem completion and intelligence. Mild impairments on executive tests and digit span performance were largely caused by the poor performance of the Korsakoff patients. The amnesics also showed remote memory deficits for personal and public domain information, and temporal gradients were observed for some of the tests. These deficits probably arose because the patients' anterograde amnesia was more severe than their retrograde amnesia even for the recent pre-morbid past. They were more impaired in the recall of details about famous names in their ability to recognize such names. There was also a suggestion that performance on anterograde tests did not relate strongly to that on tests of retrograde amnesia of the remote pre-morbid past. However, this effect was less apparent with memory for personal information when the format and the information tapped were matched on pre- and post-morbid tests.


Subject(s)
Alcohol Amnestic Disorder/diagnosis , Amnesia, Retrograde/diagnosis , Amnesia/diagnosis , Brain Damage, Chronic/diagnosis , Adult , Aged , Alcohol Amnestic Disorder/physiopathology , Alcohol Amnestic Disorder/psychology , Amnesia/physiopathology , Amnesia/psychology , Amnesia, Retrograde/physiopathology , Amnesia, Retrograde/psychology , Brain Damage, Chronic/physiopathology , Brain Damage, Chronic/psychology , Brain Mapping , Cerebral Infarction/diagnosis , Cerebral Infarction/physiopathology , Cerebral Infarction/psychology , Female , Frontal Lobe/physiopathology , Humans , Intelligence/physiology , Male , Memory, Short-Term/physiology , Mental Recall/physiology , Middle Aged , Neuropsychological Tests , Pattern Recognition, Visual/physiology , Retention, Psychology/physiology , Temporal Lobe/physiopathology , Thalamic Diseases/diagnosis , Thalamic Diseases/physiopathology , Thalamic Diseases/psychology , Thalamus/physiopathology , Verbal Learning/physiology
12.
Am J Med Sci ; 309(6): 315-6, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7771501

ABSTRACT

Pimozide is a diphenylpiperidine neuroleptic with well characterized cardiovascular side effects including QT prolongation. So far, life-threatening cardiac arrhythmias, in particular torsades de pointes, have not been described in patients treated with pimozide. The authors describe a patient in whom torsades de pointes developed after the ingestion of 800 mg pimozide as a suicide attempt. After intravenous treatment with lidocaine and magnesium, the patient recovered completely and the QT interval had normalized 5 days after the intoxication. Potential mechanisms leading to torsades de pointes in patients treated with pimozide are discussed.


Subject(s)
Pimozide/poisoning , Suicide, Attempted , Torsades de Pointes/etiology , Electrocardiography , Female , Humans , Lidocaine/therapeutic use , Magnesium/therapeutic use , Middle Aged , Schizophrenia , Torsades de Pointes/drug therapy , Torsades de Pointes/physiopathology
13.
Nuklearmedizin ; 52(1): 43-50, 2013.
Article in German | MEDLINE | ID: mdl-23348688

ABSTRACT

UNLABELLED: Aim of the study was to determine the annual incorporation of staff on a radioiodine therapy ward and the resulting annual effective dose (aed). Following the German incorporation guideline (gig), incorporation monitoring is not necessary for potential aed below 0.5 mSv/a. For aed > 0.5 mSv/a adherence to the 1 mSv dose limit must be verified. For doses > 1 mSv/a incorporation has to be monitored by the authority. Furthermore, the (131)I incorporation factor from the gig should be verified. METHODS: To determine the actual work related incorporation, the (131)I activity concentration in urine samples (collection over 24 h) of 14 employees of different professions were examined over a period of 27 months. RESULTS: Measured activity concentrations were related to the individual time of exposure. A constant activity supply for at least three days was assumed. The mean annual effective doses were 2.4 · 10⁻¹ mSv/a (nursing staff; n = 3), 5.6 · 10⁻² mSv/a (cleaning staff; n = 2), 2.8 · 10⁻³ mSv/a (technical staff; n = 2) and 5.2 · 10⁻³ mSv/a (physicians; n = 7). All aed were below the dose limits of the gig. The calculated mean incorporation factors ranged from 3.0 · 10⁻8 for the nursing staff to 3.6 · 10⁻¹° for the technical staff (cleaning staff: 7 · 10⁻9; physicians: 6.5 · 10⁻¹°) and were therefore well below the (131)I incorporation factor defined by the gig. CONCLUSIONS: To estimate the aed caused by incorporation of (131)I it has to be subdivided for the different requirements in the diverse fields of activity of the employees. Regarding those who spend most of their time nearby the patient an incorporation monitoring by the authority might be required. The (131)I incorporation factor from the guideline (10⁻6) can be reduced by a factor of 10. For (99m)Tc and (18)F an incorporation factor of 10⁻7 is accepted.


Subject(s)
Iodine Radioisotopes/analysis , Iodine Radioisotopes/therapeutic use , Occupational Exposure/analysis , Occupational Exposure/prevention & control , Radiation Monitoring/methods , Radiation Protection/methods , Humans , Radiation Dosage , Safety Management/methods , Safety Management/organization & administration
14.
Clin Exp Immunol ; 146(2): 344-53, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17034588

ABSTRACT

Vaccinia virus (VV) has been tested as oncolytic virus against malignant melanoma in clinical trials for more than 40 years. Until now, mainly strains comparable to viral strains used for smallpox vaccination have been probed for anti-tumoral therapy. We have shown recently that the wild-type strain Western Reserve (WR) can interfere with crucial functions of monocyte-derived dendritic cells (DCs). Our aim was to examine whether viral immune evasion mechanisms might be responsible for the ineffectiveness of WR-based vaccination strategies and whether the highly attenuated strain modified virus Ankara (MVA) differs from WR with respect to its possible immunostimulatory capacity after intratumoral injection. Using in vitro experiments, we compared the effect of both strains on melanoma cells and on local bystander DCs. We found that both VV-strains infected melanoma cells efficiently and caused disintegration of the actin cytoskeleton, as shown by fluorescence microscopy. In addition, both VV-strains caused apoptotic cell death in melanoma cells after infection. In contrast to MVA, WR underwent a complete viral replication cycle in melanoma cells. Bystander DCs were consecutively infected by newly generated WR virions and lost their capacity to induce allogeneic T cell proliferation. DCs in contact with MVA-infected melanoma cells retained their capacity to induce T cell proliferation. Immature DCs were capable of phagocytosing MVA-infected melanoma cells. Priming of autologous CD8(+) T cells by DCs that had phagocytosed MVA-infected, MelanA positive melanoma cells resulted in the induction of T cell clones specifically reactive against the model antigen MelanA as shown by enzyme-linked immunospot (ELISPOT) analysis. We conclude that the clinical trials with oncolytic wild-type VV failed probably because of suppression of bystander DCs and consecutive suppression of T cell-mediated anti-melanoma immunity. The attenuated VV-strain MVA facilitates the generation of tumour associated antigen (TAA)-specific T cell response as it is oncolytic for melanoma cells, but non-toxic for DC, and should be a promising candidate for intralesional metastatic melanoma therapy.


Subject(s)
Apoptosis/immunology , Cancer Vaccines/immunology , Dendritic Cells/immunology , Melanoma/immunology , Vaccinia virus/immunology , Actins/metabolism , Bystander Effect/immunology , Cytoskeleton/pathology , Humans , Melanoma/pathology , Melanoma/virology , Phagocytosis , Tumor Cells, Cultured , Vaccines, Attenuated/immunology , Vaccinia virus/classification , Vaccinia virus/physiology , Virus Replication
15.
Gene Ther ; 13(1): 52-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16107861

ABSTRACT

Targeted antiangiogenic gene therapy is an attractive approach to treat metastatic cancer. However, the relative paucity of the receptors of the commonly used adenovirus serotype 5 in endothelial cells as compared with liver cells undermines the use of this vector for targeting the endothelial cells in tumors. To overcome this problem, we analyzed the ability of a hybrid Ad5/35 virus, where the serotype 5 fiber has been replaced with the fiber from serotype 35, to target tumor vasculature. Infection of human umbilical vein endothelial cells (HUVECs) with Ad5/35 at MOI 120 infected 100% of cells. In contrast, infection with Ad5 at the same MOI infected only 10% HUVECs. Ad5/35 was even more effective in transducing human aortic endothelial cells (HAECs), as infection with Ad5/35 at MOI 3.6 was sufficient to transduce 95% of cells. Gene expression analyses demonstrated that infection of HUVECs and HAECs with Ad5/35 resulted in between 1 and 3 orders of magnitude higher gene expression than infection with Ad5. Furthermore, various liver-derived cells were less infectable with Ad5/35 than Ad5, indicating a favorable toxicity profile for this virus. In a rat colon carcinoma tumor model, Ad5 was located mainly in the liver parenchyma after hepatic artery administration. In contrast, Ad5/35 was found only in the angiogenesis-rich border region of the tumor. Double immunostaining revealed that Ad5/35 colocalized with CD31 and Flk-1 positive endothelial cells. These results indicate that Ad5/35 may be useful in anticancer strategies targeting tumor endothelial cells.


Subject(s)
Adenoviruses, Human/genetics , Capsid Proteins/genetics , Endothelial Cells/virology , Genetic Therapy/methods , Neovascularization, Pathologic/therapy , Transduction, Genetic/methods , Animals , Biomarkers/analysis , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/therapy , Genetic Vectors/administration & dosage , Humans , Liver Neoplasms/blood supply , Liver Neoplasms/therapy , Models, Animal , Neovascularization, Pathologic/virology , Platelet Endothelial Cell Adhesion Molecule-1/analysis , Rats , Tumor Cells, Cultured , Vascular Endothelial Growth Factor Receptor-2/analysis
16.
Am J Transplant ; 6(11): 2786-90, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16952300

ABSTRACT

Diagnosis of intestinal transplant rejection depends on clinical assessment, endoscopy and most importantly, histology of intestinal biopsies. Plasma citrulline levels (P-Cit) reflect functional enterocyte mass in nontransplant patients and have been evaluated in two small series after transplant. This study was designed to determine the sensitivity and specificity of P-Cit as diagnostic tool for allograft injury, especially to distinguish between viral enteritis and rejection. We prospectively collected 403 P-Cit samples within 24 h of intestinal biopsy in 49 patients. P-Cit levels were correlated with the mucosal damage and histopathological diagnoses. P-Cit levels in bowels with significant mucosal damage (i.e. moderate or severe rejection, viral enteritis, PTLD, ischemia reperfusion injury, allergic enteritis) were significantly lower than in intestines with no or mild injury (i.e. indeterminate or mild rejection, nonspecific enteritis): 22.9 +/- 15.4 versus 38 +/- 23.2 nmol/mL (p < 0.0001). Sensitivity and specificity of the test were 80% and 58.1% for rejection, and 56.5% and 66% for viral enteritis, thereby unable to distinguish between both entities. In conclusion, P-Cit reflects the extent of mucosal injury regardless of the etiology, but does not seem to be a predictive marker for rejection or viral enteritis, as its values may decline only when diffuse mucosal damage has occurred.


Subject(s)
Citrulline/blood , Intestinal Mucosa/pathology , Intestines/transplantation , Biomarkers/blood , Biopsy , Humans , Intestinal Mucosa/injuries , Postoperative Complications/blood , Reproducibility of Results , Transplantation, Homologous/pathology
18.
Gene Ther ; 12(20): 1526-33, 2005 Oct.
Article in English | MEDLINE | ID: mdl-15973445

ABSTRACT

We have previously shown that the local-membrane bound 4-1BB ligand and IL-12 gene transfer induced a significant antitumor response in a mouse colon carcinoma model. However, a high viral dose was required in order to achieve the best efficacy. In this study, we hypothesize that the systemic administration of soluble Ig-4-1BB ligand can give rise to better T-cell immune activation than local gene delivery. With potential clinical applications in mind, we further compare whether the natural 4-1BB ligand fused to mouse IgG2a (Ig-4-1BBL) would be as effective as the agonistic anti-4-1BB antibody. The dimeric form of Ig-4-1BBL was purified from HeLa cells transduced with a recombinant adenovirus (ADV/Ig-4-1BBL) expressing Ig-4-1BBL. Functional activity was confirmed by the ligand's ability to bind to activated splenic T cells or bone marrow (BM)-derived dendritic cells (DCs) that express 4-1BB receptor. The soluble Ig-4-1BBL efficiently costimulated CD3-activated T-cell proliferation in vitro. More importantly, it induced tumor-specific CTLs as effectively as the agonistic anti-4-1BB antibody. When combined with IL-12 gene transfer, systemic administration of the Ig-4-1BBL proved to be more potent than local gene delivery. In addition, the Ig-4-1BBL is as potent as the agonistic anti-4-1BB antibody for the treatment of hepatic MCA26 colon carcinoma, resulting in 50% complete tumor regression and long-term survival. In long-term surviving mice, both treatment modalities induced persistent tumor-specific CTL activity. In summary, these results suggest that the systemic delivery of Ig-4-1BBL can generate a better antitumor response than local gene delivery. Ig-4-1BBL had equivalent biological functions when compared to the agonistic anti-4-1BB antibody. Thus, soluble 4-1BBL dimmer can be developed as a promising agent for cancer therapy in humans.


Subject(s)
Genetic Therapy/methods , Immunoglobulin G/genetics , Immunotherapy/methods , Interleukin-12/genetics , Neoplasms, Experimental/therapy , Tumor Necrosis Factors/genetics , 4-1BB Ligand , Adenoviridae/genetics , Animals , Antibodies/administration & dosage , Cell Line, Tumor , Cells, Cultured , Colonic Neoplasms/immunology , Colonic Neoplasms/therapy , Dendritic Cells/immunology , Genetic Vectors/administration & dosage , Interleukin-12/immunology , Killer Cells, Natural/immunology , Liver Neoplasms/immunology , Liver Neoplasms/therapy , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Neoplasms, Experimental/immunology , Recombinant Fusion Proteins/administration & dosage , Spleen/cytology , Spleen/immunology , T-Lymphocytes, Cytotoxic/immunology , Transduction, Genetic/methods , Tumor Necrosis Factors/immunology
19.
Hautarzt ; 47(9): 711-5, 1996 Sep.
Article in German | MEDLINE | ID: mdl-8999029

ABSTRACT

We report a patient who developed malignant transformation of a cellular blue nevus. At the age of 19 years the congenital, pigmented tumor on the left buttock was histopathologically diagnosed as cellular blue nevus. Thirty years later the tumor dramatically increased in size, involving the entire left buttock within several months. Multiple biopsies revealed the presence of a cellular blue nevus within the papillary dermis and an invasive, pleomorphic pigmented sarcoma in the depth of the tissue spreading into subcutis and skeletal muscle. Both benign and malignant cells were S100+, vimentin+ and HMB-45+, but only the malignant tumor cells stained positive for the proliferating cell nuclear antigen. General examination disclosed multiple metastases in the paraaortal lymph nodes and the retroperitoneum as well as a single brain metastasis. Despite palliative therapy with ionizing radiation and chemotherapy, the patient developed generalized metastases and died within weeks. This case clearly confirms that cellular blue nevi have the potential for malignant transformation and that the malignant variant may behave aggressively just as a malignant melanoma.


Subject(s)
Brain Neoplasms/secondary , Lymph Nodes/pathology , Nevus, Blue/secondary , Skin Neoplasms/pathology , Biomarkers, Tumor/analysis , Brain/pathology , Brain Neoplasms/pathology , Buttocks , Cell Division/physiology , Cell Transformation, Neoplastic/pathology , Humans , Lymphatic Metastasis , Male , Middle Aged , Nevus, Blue/congenital , Nevus, Blue/pathology , Skin/pathology , Skin Neoplasms/congenital
20.
Parasite Immunol ; 23(4): 195-201, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11298296

ABSTRACT

Dendritic cells (DC) are sentinels of immunity. We determined their role in the induction of immunity against alveolar echinococcosis, caused by the larval stage of the cestode Echinococcus multilocularis. Furthermore, we evaluated if unfractionated protein from E. multilocularis (Em-Ag) can be used as loading agent for DC (comparable to unfractionated tumour proteins) in order to generate antiparasitic cytotoxic T lymphocyte (CTL). Interestingly, immature DC did not mature in the presence of 1 microg/ml Em-Ag as analysed by FACS and mixed leucocyte reactions. Yet, their capacity to take up dextran was markedly reduced. Further maturation of immature Em-Ag pulsed DC could be induced by proinflammatory cytokines. These mature DC were slightly better inducers of T cell proliferation when compared with unpulsed mature DC. Importantly, by repetetive stimulation of autologous CD8+ lymphocytes with the Em-Ag pulsed mature DC, we were able to generate specifically proliferating CTL lines. Thus, immunotherapy with ex vivo generated Em-Ag pulsed DC might be of benefit for patients inheriting this incurable disease.


Subject(s)
Antigens, Helminth/immunology , Dendritic Cells/immunology , Helminth Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Antigen Presentation/immunology , Cell Count , Cells, Cultured , Dendritic Cells/cytology , Echinococcus/immunology , Flow Cytometry , Humans
SELECTION OF CITATIONS
SEARCH DETAIL